Close Menu

NEW YORK − Hutchison Medipharma, a subsidiary of Chi-Med, said on Friday that it has started a Phase I trial in China for HMPL-306 in patients with IDH1 and IDH2-mutated relapsed or refractory myeloid leukemia or neoplasms and has dosed the first patient.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.